Search

To evaluate the changes in choriocapillaris (CC)/Sattler and Haller layer thicknesses in eyes with neovascular age-related macular degeneration (nAMD) after aflibercept or ranibizumab injections.Retrospective.A total of 70 eyes of 70 patients with treatment-naïve exudative nAMD were treated with 3 consecutive injections of aflibercept (IVA) or ranibizumab (IVR). CC/Sattler and Haller layer thicknesses were measured at the nasal and temporal regions 1000 µm from the center of the fovea by enhanced-depth imaging optical coherence tomography at baseline and after the 3 monthly intravitreal injections. In addition, the hyperfluorescence region (HF) was measured as the largest horizontal diameter of the hyperfluorescence area on the early-middle phase fluorescein angiographic images at baseline and after the 3 loading doses.After the 3 consecutive injections, the mean reductions in the nasal/temporal CC/Sattler layer thicknesses in the IVR and IVA groups were - 10.1 ± 2.3/ - 8.5 ± 1.8 and - 25.2 ± 15.2/ - 19.4 ± 12.8 μm, respectively. Also, the mean reductions in the nasal/temporal Haller layer thicknesses in the IVR and IVA groups were - 6.5 ± 3.6/ - 7.2 ± 7.9 and - 9.5 ± 8.0/ - 7.0 ± 6.2 μm, respectively. The changes in the CC/Sattler layer thicknesses of the IVA group were greater than those of the IVR group (P .001); however, the changes in the Haller layer thickness were similar between the groups (P .05). The mean decrease in the HF size of the IVA group was greater than that of the IVR group (P .001).Aflibercept treatment has a more pronounced effect on the CC/Sattler layer. Such results may indicate that aflibercept treatment influences choroidal neovascularization, possibly by reducing the capillary permeability associated with active neovascularization in the CC layer.

Purpose To examine possible changes in Scheimpflug corneal densitometry 12 months after trabeculectomy and compare these measurements with healthy controls. Methods In the patient group, corneal densitometry with Scheimpflug Pentacam HR corneal topography was evaluated in three different corneal regions (0–2, 2–6, 6–10 mm) and four quadrants (upper, lower, temporal, nasal) before trabeculectomy and 12 months after surgery. It was compared with the control group. The number and duration of use of IOP-lowering agents, daily applications, and benzalkonium chloride (BAC) content were recorded before surgery. Results Mean IOP from 25.8 ± 4.7 to 14.5 ± 3.0 mm Hg (p 0.05). Conclusion Glaucoma surgeries not only reduce eye pressure but also protect corneal health.

To objectively evaluate changes in lens densitometry in eyes with neovascular age-related macular degeneration (n-AMD) treated with repeated intravitreal ranibizumab injections during a 12-month period and to compare the results with those in untreated healthy fellow eyes and healthy control eyes.In this prospective study, the 36 treated eyes and the 37 untreated fellow eyes of 38 patients with n-AMD and the 32 control eyes of 32 healthy individuals were analyzed. Lens densitometry was evaluated using the Scheimpflug imaging. All data in both groups regarding lens densitometry were recorded at baseline and 12 months.The mean densitometry of zone 1 in the treated eyes of patients had increased significantly at 12 months compared with the baseline (baseline: 9.3 ± 1.5, 12 months: 11.9 ± 1.7, p = .004) and was significantly greater than those measurements in the fellow eyes (9.8 ± 1.6 p = .02) and control eyes (9.6 ± 1.9, p = .01) at 12 months as well. There were no significant differences in terms of densitometry values between the fellow and control eyes at baseline and 12 months (for all, p .05).Our results objectively demonstrate early nuclear lens density changes using with Scheimpflug images in eyes with n-AMD that were treated with repeated ranibizumab injections for 12 months.

Purpose : To compare the differences in retinal vascular structure and choroidal thickness between the active disease and post-recovery periods in COVID-19 patients and healthy controls. Material and Methods : This prospective, cross-sectional study included 30 eyes from 30 patients with severe COVID-19 and 30 eyes of 30 sex-matched healthy controls. Central macular thickness (CMT), subfoveal choroidal thickness (CT) and retinal vascular changes of patients were measured after positive polymerase chain reaction (PCR) (where the patient had COVID-19-related symptoms) and then three months after two negative PCRs. Laboratory parameters, including C-reactive protein and D-dimer levels, were also recorded. Results : The mean age of the patients was 47.90 ± 9.06 years in patients group, 49.07 ± 8.41 years in control goups (p=0.467). In terms of choroidal thicknesses subfoveal, nasal and temporal region were significantly higher in the active disease period than control group (p=0.019, p=0.036, p=0.003, respectively). When the after recovery period was compared with the control group in terms of choroidal thickness, although the choroidal thickness was higher in all regions, this difference was not found statistically significant. There was no statistically significant difference in CMT between groups (p=0.506).The mean venous and arterial wall thicknesses were significantly higher in the active period than after recovery (p=0.023, p=0.013, respectively) but there were no differences between after recovery and control groups in the pairwise comparison (p=0.851, p=0.715, respectively). Conclusion : In patients with severe COVID-19, there are changes in thickness of the choroid and retinal vessel walls. While vascular wall thickness increases due to inflammation, the absence of lumen changes may be associated with hemodynamic variables.